Abstract: Disclosed is an off-road motorcycle, which comprises a frame and a rear fork pivotally connected to the frame, by arranging two connecting rods in different positions, which are namely a first connecting rod and a second connecting rod, when a shock absorption action is needed, by means of a quadrilateral principle, the first connecting rod is subjected to an acting force after deflection of the rear fork and the acting force is progressively dispersed to the second connecting rod until the acting force is transmitted to a shock absorber, so as to form a two-stage acting force, thereby obtaining a better shock absorption effect.

Abstract: The present invention relates to heterocyclic compounds or their pharmaceutically acceptable salts as VAV1 protein degraders. Specifically, the invention relates to compounds of Formula I and their pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing the compounds of the present invention. The compounds of the present invention can be used for the treatment and/or prevention of VAV1-mediated diseases, including autoimmune and inflammatory diseases, and cancers.

Abstract: Disclosed are a system, a method, and storage medium for controlling a hydrogen refueling action of a fuel cell vehicle. The method includes: obtaining a structural design parameter of a hydrogen system of the fuel cell vehicle and a driving data set of the fuel cell vehicle; determining a first hydrogen refueling feature set and a second hydrogen refueling feature set of the fuel cell vehicle; determining whether the fuel cell vehicle is in a high hydrogen consumption state; generating a consumption reduction command and sending the consumption reduction command to a vehicle control unit; and controlling, by the vehicle control unit based on the consumption reduction command, a fuel cell control unit (FCU) to adjust an injection frequency of a hydrogen injector, and controlling a motor control unit (MCU) to set a peak threshold of a stator current to limit a maximum phase current of a motor.

Abstract: A dual-control system for an electric bicycle and a switching method for velocity and torque drive for an electric bicycle are disclosed. A dual-driven algorithm controller provided by the present application receives instructions from an instrument communication signal module, interacts with a bilateral single-direction signal magnetic detection torque sensor to obtain velocity signals or torque signals, and then outputs a corresponding velocity or torque through a field oriented control (FOC) motor control module; and the bilateral single-direction signal magnetic detection torque sensor is configured to convert the twist deformation of a bottom bracket in a pedal of an electric bicycle into electrical signals.

Abstract: The present invention relates to heterocyclic compounds or their pharmaceutically acceptable salts as VAV1 protein degraders. Specifically, the invention relates to compounds of Formula I and their pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing the compounds of the present invention. The compounds of the present invention can be used for the treatment and/or prevention of VAV1-mediated diseases, including autoimmune and inflammatory diseases, and cancers.

Abstract: A method for preparing orelabrutinib and an intermediate compound thereof. Specifically, the present disclosure relates to a method for preparing 6-(1-acryloylpiperidin-4-yl)-2-(phenoxyphenyl)pyridine-3-carboxamide and an intermediate compound thereof. The preparation method features simple route, inexpensive and easily available raw materials, mild conditions, and a high product yield. It can greatly reduce the production cost, is environmentally friendly, and is easily adaptable to industrial-scale production.

Abstract: The present invention relates to bridged bicyclic Compounds A and B or their pharmaceutically acceptable salts thereof as inhibitors of Bruton's tyrosine kinase (BTK) and its C481 mutant. The present invention also relates to methods for preparing Compounds A and B or their pharmaceutically acceptable salts thereof. Compounds of the present invention can be used to treat and/or prevent related diseases mediated by BTK or its C481 mutant, especially cancer and autoimmune diseases.

Abstract: Heterocyclic compounds shown in Formula (I) suitable for inhibiting or regulating the activity of Janus kinase (JAK), particularly tyrosine kinase 2 (TYK2). The compounds are useful for preventing and/or treating relevant JAK-mediated diseases, such as autoimmune diseases, inflammatory diseases, and cancers.

Abstract: The present invention relates to compounds suitable for inhibiting or regulating the activity of IL-17. The present invention is directed to compounds shown in Formula (I) and their pharmaceutically acceptable salts thereof. The present invention further relates to methods for treating and/or preventing various human diseases, including inflammatory and autoimmune disorders. The present invention also provides methods for preparing the compounds of the present invention.

Abstract: A dual-control system for an electric bicycle and a switching method for velocity and torque drive for an electric bicycle are disclosed. A dual-driven algorithm controller provided by the present application receives instructions from an instrument communication signal module, interacts with a bilateral single-direction signal magnetic detection torque sensor to obtain velocity signals or torque signals, and then outputs a corresponding velocity or torque through a field oriented control (FOC) motor control module; and the bilateral single-direction signal magnetic detection torque sensor is configured to convert the twist deformation of a bottom bracket in a pedal of an electric bicycle into electrical signals.

Abstract: The present invention relates to an amorphous solid dispersion comprises (S)-1-(1-acryloylpyrrolidin-3-yl)-3-((3,5-dimethoxyphenyl)ethynyl)-5-(methylamino)-1H-pyrazole-4-carboxamide (Compound I) and a pharmaceutically acceptable polymer. The present invention also relates to a pharmaceutical composition comprising the amorphous solid dispersion. The amorphous solid dispersion of the present invention is stable upon storage and provides better solubility and bioavailability when comparing with a crystalline form.

Abstract: Heterocyclic compounds shown in Formula (I) suitable for inhibiting or regulating the activity of Janus kinase (JAK), particularly tyrosine kinase 2 (TYK2). The compounds are useful for preventing and/or treating relevant JAK-mediated diseases, such as autoimmune diseases, inflammatory diseases, and cancers.